BIOTON SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLBIOTN00029
PLN
3.98
-0.02 (-0.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 1.05%

  • The company has been able to generate a Return on Equity (avg) of 1.05% signifying low profitability per unit of shareholders funds
2

Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.46 times

3

Poor long term growth as Net Sales has grown by an annual rate of 9.87% and Operating profit at 52.69% over the last 5 years

 
4

With a growth in Net Profit of 30.4%, the company declared Outstanding results in Mar 25

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 343 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.05

stock-summary
Return on Equity

-0.45%

stock-summary
Price to Book

0.58

Revenue and Profits:
Net Sales:
66 Million
(Quarterly Results - Mar 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.56%
0%
-4.56%
6 Months
-2.93%
0%
-2.93%
1 Year
31.35%
0%
31.35%
2 Years
10.1%
0%
10.1%
3 Years
11.95%
0%
11.95%
4 Years
-10.16%
0%
-10.16%
5 Years
-9.24%
0%
-9.24%

BIOTON SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
9.87%
EBIT Growth (5y)
52.69%
EBIT to Interest (avg)
1.41
Debt to EBITDA (avg)
1.46
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.34
Tax Ratio
29.59%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.00%
ROE (avg)
1.05%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.62
EV to EBIT
108.94
EV to EBITDA
9.61
EV to Capital Employed
0.64
EV to Sales
1.49
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.59%
ROE (Latest)
-1.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -15.57% vs 85.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -28.89% vs -32.35% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "65.60",
          "val2": "77.70",
          "chgp": "-15.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.50",
          "val2": "13.10",
          "chgp": "-50.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.20",
          "val2": "2.70",
          "chgp": "-18.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.80",
          "val2": "-4.50",
          "chgp": "-28.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-64.60%",
          "val2": "47.30%",
          "chgp": "-11.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.43% vs -22.13% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -782.61% vs 64.29% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "207.80",
          "val2": "181.60",
          "chgp": "14.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "23.20",
          "val2": "23.90",
          "chgp": "-2.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.20",
          "val2": "8.40",
          "chgp": "-2.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "16.00",
          "chgp": "-99.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.70",
          "val2": "2.30",
          "chgp": "-782.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-29.50%",
          "val2": "-23.70%",
          "chgp": "-0.58%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
65.60
77.70
-15.57%
Operating Profit (PBDIT) excl Other Income
6.50
13.10
-50.38%
Interest
2.20
2.70
-18.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.80
-4.50
-28.89%
Operating Profit Margin (Excl OI)
-64.60%
47.30%
-11.19%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is -15.57% vs 85.00% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -28.89% vs -32.35% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
207.80
181.60
14.43%
Operating Profit (PBDIT) excl Other Income
23.20
23.90
-2.93%
Interest
8.20
8.40
-2.38%
Exceptional Items
0.10
16.00
-99.38%
Consolidate Net Profit
-15.70
2.30
-782.61%
Operating Profit Margin (Excl OI)
-29.50%
-23.70%
-0.58%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 14.43% vs -22.13% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -782.61% vs 64.29% in Dec 2023

stock-summaryCompany CV
About BIOTON SA stock-summary
stock-summary
BIOTON SA
Pharmaceuticals & Biotechnology
Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
Company Coordinates stock-summary
Company Details
Ul. Staroscinska 5 , WARSZAWA None : 02-516
stock-summary
Tel: 48 22 721400048 22 4401440
stock-summary
Registrar Details